대마초 사용 장애 치료를 위한 티르제파타이드 임상시험
대마초 사용 장애(CUD) 치료를 위한 티르제파타이드의 무작위, 이중 맹검, 위약 대조 파일럿 임상시험
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a double-blind, placebo-controlled, randomized clinical trial. 100 individuals with moderate to severe cannabis use disorder (CUD) will be randomized in a 1:1 ratio to receive either (1) weekly subcutaneous injections of tirzepatide or (2) weekly subcutaneous injections of matching placebo for 24 weeks. Tirzepatide will be initiated at 2.5 mg for 4 weeks (4 injections) and increased in 2.5 mg increments every 4 weeks as tolerated, up to a maximum dose of 15 mg.
The Primary Objective is to determine the maximum tolerated dose (MTD) of tirzepatide in individuals with CUD and to evaluate its efficacy in reducing cannabis use.
The primary Hypothesis is that tirzepatide will be well tolerated within the FDA-recommended dose range and compared with placebo, it will result in a significantly greater proportion of cannabis abstinent days as measured by the timeline follow-back (TLFB).
Secondary Objectives are to evaluate the effects of tirzepatide, relative to placebo, on (1) CUD severity based on DSM-5 criteria; (2) percentage of cannabis-negative weekly urine drug screens collected during the treatment period; (3) cannabis craving; (4) cannabis withdrawal severity; (5) retention in treatment; and (6) quality of life.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jana Drgonova, PhD
- 전화번호: 301-827-5933
- 이메일: jana.drgonova@nih.gov
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Between 18 and 70 years of age
- Meets DSM-5 criteria for moderate or severe CUD
- Interested in treatment for cannabis use disorder
- Able to understand the study procedures and written informed consent in English
- Willing to comply with all study procedures and medication instructions
- If female, is not pregnant, and agrees to use acceptable birth control methods
Exclusion Criteria:
- Body Mass Index (BMI) ≤ 23 kg/m²
- Presence of a medical or psychiatric disorder that contraindicates participation in the study
- Substance use disorder other than tobacco or mild alcohol-use disorder
- Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product
- Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug
- Current or recent (past 6 months) enrollment in substance use disorder treatment
- Current or planned pregnancy and breastfeeding
- Living or medical situation that would interfere with adherence to the study protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Participants will receive weekly masked injections of placebo. |
|
실험적: 액티브 트리트먼트
|
Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will be made based on the Dose Increase Checklist and shared decision between the site study physician (MD or DO) and the participant. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
기간: 24 weeks (Treatment Phase)
|
The maximum tolerated dose defined as the median dose within the FDA-recommended range, at which dose increase is not recommended (based on standardized and health care provider assessments). |
24 weeks (Treatment Phase)
|
|
Days of Abstinence
기간: 24 weeks (Treatment Phase)
|
Number of days per week with no cannabis use, as assessed by Timeline Follow Back (TLFB). |
24 weeks (Treatment Phase)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Severity of Cannabis Use Disorder (CUD)
기간: 24 weeks (Treatment Phase)
|
Severity of CUD as determined by DSM-5 criteria for Cannabis Use Disorder Checklist and expressed as a number of reported symptoms |
24 weeks (Treatment Phase)
|
|
Negative Urine Drug Screens (UDS)
기간: 24 weeks (Treatment Phase)
|
Percentage of weekly urine drug screens testing negative for cannabis out of all scheduled weekly drug screens. |
24 weeks (Treatment Phase)
|
|
Cannabis Craving
기간: 24 weeks (Treatment Phase)
|
Cannabis Craving as assessed by the short form of the Marijuana Craving Questionnaire (MCQ) and expressed as a score. The score range is 12-84, and the higher score indicates a higher or more frequent level of craving. |
24 weeks (Treatment Phase)
|
|
1. Cannabis Withdrawal
기간: 24 weeks (Treatment Phase)
|
Cannabis withdrawal as assessed by the DSM 5 Cannabis Withdrawal Checklist and expressed as a number of symptoms present (up to 7) |
24 weeks (Treatment Phase)
|
|
Retention in Treatment
기간: Week 24 (End of Treatment Phase)
|
Percentage of randomized participants who receive study medication during the treatment phase. |
Week 24 (End of Treatment Phase)
|
|
Quality of Life
기간: 24 weeks (Treatment Phase)
|
Quality of life (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain intensity) as determined by PROMIS-29 questionnaire and expressed as a score. The domain scores (T-scores) range is 20-80 with higher scores representing better outcomes. |
24 weeks (Treatment Phase)
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Jia Bei Wang, MD, PhD, NIDA/NIH, Division of Therapeutics and Medical Consequences (DTMC)
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- NIDA/VA CS #1037
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .